Protocol Ledger

NCT05821959 · Phase III · RECRUITING

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

Interventional Phase III clinical trial protocol NCT05821959 sponsored by Eli Lilly and Company in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-15 Enrollment: 48 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05821959
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05821959
Protocol FieldVerified Registry Value
NCT IdentifierNCT05821959
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment48 participants (ESTIMATED)
Registered Start Date2023-09-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI